INDV Indivior Pharmaceuticals, Inc.

Healthcare stocks were edging higher pre-bell Wednesday, with the State Street Health Care Select Se

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.

Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Indivior Pharmaceuticals Inc. (INDV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Indivior Pharmaceuticals Inc. (INDV) possesses solid growth attributes, which could help it handily outperform the market.

Indivior Pharmaceuticals (INDV) recently drew investor attention after a period of mixed share performance, with the stock down 9% over the past month but still higher year to date. This move has prompted fresh questions about valuation. See our latest analysis for Indivior Pharmaceuticals. At the current share price of $36.87, Indivior Pharmaceuticals has seen short term momentum fade, with a 1 month share price return that declined 8.85%, although the 1 year total shareholder return of...

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.

Indivior Pharmaceuticals Inc. (INDV) possesses solid growth attributes, which could help it handily outperform the market.

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The t

Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stocks attempted to extend their recovery following July’s sharp pullback.

Indivior Pharmaceuticals Inc. (INDV) delivered earnings and revenue surprises of +18.56% and +11.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV) said Monday that they will merge

Opioid addiction has cast a shadow over the U.S. But this pharma stock, which targets the issue, is eyeing a fresh entry as profits soar.

Howard Marks just filed five equity positions that look nothing like a bull-market portfolio, and every one has moved sharply since he bought. The question now is whether his thesis still holds at today's prices.